This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=7 http://www.lsis.com/goto/r7/rss 2012-02-05T11:10:10+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 Melbourne, Australia; 1 February 2012: Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere) in a breast cancer model. Docetaxel is a leading chemotherapy drug used to treat a wide range of solid tumours including breast, lung and prostate. It is marketed by Sanofi Aventis (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8106045 |-| Title: 2-morpholino-4-pyrimidone compound |-| Inventors: Watanabe; Kazutoshi (Tokyo, JP), Uehara; Fumiaki (Tokyo, JP), Hiki; Shinsuke (Tokyo, JP), Kohara; Toshiyuki (Tokyo, JP), Fukunaga; Kenji (Tokyo, JP), Yokoshima; Satoshi (Tokyo, JP) |-| Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka, JP) Sanofi-Aventis (Paris, FR) |-| A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8106023 |-| Title: 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof |-| Inventors: Glombik; Heiner (Frankfurt am Main, DE), Frick; Wendelin (Frankfurt am Main, DE), Theis; Stefan (Frankfurt am Main, DE), Heuer; Hubert (Frankfurt am Main, DE), Schaefer; Hans-Ludwig (Frankfurt am Main, DE), Kramer; Werner (Frankfurt am Main, DE) |-| Assignee: Sanofi-Aventis Deutschland GmbH (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8106099 |-| Title: Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias |-| Inventors: Brendel; Joachim (Bad Vilbel, DE), Wirth; Klaus (Kriftel, DE), Goegelein; Heinz (Frankfurt, DE), Allessie; Maurits (Maastricht, NL), Blaauw; Yuri (Maastricht, NL) |-| Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt Am Main, DE) |-| The invention relates to the combination of one or more IK.sub.r channel blockers (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 BACKGROUND: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass grafting (CABG) surgery. The objective of this study was to determine the impact of POAF on both short- and long-term mortality following isolated CABG. HYPOTHESIS: POAF is associated with a poorer short and long-term mortality following CABG. METHODS: We retrospectively analyzed the preoperative and operative data of 6728 consecutive patients undergoing a first isolated CABG. RESULTS: The (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 BACKGROUND: We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy. METHODS: In the GeparQuinto randomised phase 3 trial, patients with untreated HER2-positive operable or locally advanced breast cancer were enrolled between Nov 7, 2007, and July 9, 2010. Patients were eligible if their tumours were classified as cT3/4a-d, or hormone receptor (HR)-negative, HR-positive with clinically node-positive and cT2 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Hypertension in the elderly is a major risk factor for cardiovascular disease. We aimed to analyze determinants of blood pressure (BP) control across different age groups. Population of a large global survey on hypertension treatment and control including 18?927 patients was analyzed. A logistic regression analysis was conducted to estimate BP control rates and the prevalence of antihypertensive drug usage according to age. Systolic BP control decreased from 29.6% (95% confidence intervals (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 : To develop and psychometrically evaluate a domain-specific questionnaire to assess subtle but clinically relevant differences in treatment experiences and satisfaction over a wide range of currently available insulin therapy regimens. The study focussed on patients with type 2 diabetes mellitus and placed particular attention on the impact of different forms of insulin therapy on diabetes self-management. |-| Patient. |-| Moock J, Hessel F, Ziegeler D, Kubiak T, Kohlmann T. |-| 1 Institute (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 BERWYN, Pa.-(BUSINESS WIRE)-Formula Pharmaceuticals, a privately-held oncology drug development company, today announced the appointment of Martyn Greenacre to the Board of Directors. Mr. Greenacre served as Chairman of BMP Sunstone Corporation, a pharmaceutical company recently acquired by Sanofi-Aventis. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 PHILADELPHIA, January 23 Premier Research Group announces the appointment of Etienne Drouet to the position of Executive Director, Oncology Europe. In this position, Mr. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research s growing portfolio of oncology business. œEtienne brings a tremendous amount of operational knowledge and oncology acumen serving the needs of our customers,  said Dr. Sue Stansfield, Executive VP, Clinical (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8101583 |-| Title: 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof |-| Inventors: Glombik; Heiner (Hofheim, DE), Frick; Wendelin (Hunstetten-Beuerbach, DE), Theis; Stefan (Frankfurt, DE), Heuer; Hubert (Schwabenheim, DE), Schaefer; Hans-Ludwig (Hochheim, DE), Kramer; Werner (Mainz-Laubenheim, DE) |-| Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt, DE) |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Atrial fibrillation (AF) is the most common arrhythmia encountered by generalists and cardiologists alike. Much of the attendant morbidity from AF arises from systemic embolic complications which are effectively reduced with utilization of anti-platelet and/or anticoagulant therapy. The systemic embolic complications of AF and the medical therapy to attenuate these risks are very well established. Through the course of this review, we aim to highlight the complex relationship between AF and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Over the last decade, several rhythm-versus rate-control trails in patients with atrial fibrillation (AF) have failed to demonstrate benefit of the rhythm control strategy with respect to mortality and morbidity. This had let to the guideline recommendation that antiarrhythmic drug therapy should be considered predominantly for sympt0matic improvement of patients. Recent trails and meta-analyses have demonstrated that amiodarone is the most antiarrhythmic drug currently available. However, its (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Dr. Camm received an honorarium through an educational grant from Sanofi Aventis to serve as Guest Editor of this supplement. He discloses no other direct conflicts of interest to the submitted work. Dr. Camm has served as a consultant, received grant funding, and has been a member of the speakers bureau for Sanofi Aventis. |-| Clin Cardiol. |-| John Camm A. |-| St. George's University of London, London, United Kingdom. jcamm@sgul.ac.uk. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Stroke prevention with appropriate thromboprophylaxis still remains central to the management of atrial fibrillation (AF). Nonetheless, stroke risk in AF is not homogeneous, but despite stroke risk in AF being a continuum, prior stroke risk stratification schema have been used to 'artificially' categorise patients into low, moderate and high risk stroke strata, so that the patients at highest risk can be identified for warfarin therapy. Data from recent large cohort studies show that by being (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 OBJECTIVE: This study empirically analyzes the effects of public information about the pharmaceutical R&D process on the market valuation of the sponsoring firm. We examined the market's response to scientific news and regulatory decisions about an antiobesity drug, rimonabant, and the effects on the sponsoring company (Sanofi-Aventis) and its incumbent competitors (Abbott and Roche). METHODS: Event study methodology was used to test the null hypothesis of no market response. We covered the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8097758 |-| Title: Isoserine derivatives for use as coagulation factor IXa inhibitors |-| Inventors: Steinhagen; Henning (Sulzbach, DE), Follmann; Markus (Wulfrath, DE), Goerlitzer; Jochen (Frankfurt am Main, DE), Schreuder; Herman (Hofheim, DE) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The invention relates to the compounds of formula (I) #STR00001# having antithrombotic activity which especially inhibit blood clotting factor IXa, to methods for producing the same (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 BACKGROUND: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8093256 |-| Title: Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |-| Inventors: Lochead; Alistair (Charenton le Pont, FR), Saady; Mourad (Paris, FR), Slowinski; Franck (Thieux, FR), Yaiche; Philippe (Les Lilas, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) Mitsubishi Pharma Corporation (Osaka, JP) |-| The invention relates to use of substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: #STR00001# wherein X, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8092421 |-| Title: Dual-chamber carpule |-| Inventors: Seiferlein; Werner (Frankfurt am Main, DE), Mockel; Jorn (Frankfurt am Main, DE), Zink; Martin (Frankfurt am Main, DE) |-| Assignee: Sanofi-Aventis Deutschland GmbH (DE) |-| The invention relates to a dual-chamber carpule having (1) a first partial cylinder comprising a sealing cap, a bypass, and an intermediate stopper, (2), an optional sealing element, and (3) a second partial cylinder comprising an end stopper and, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8092422 |-| Title: Dual-chamber carpule with attachment |-| Inventors: Seiferlein; Werner (Frankfurt am Main, DE), Mockel; Jorn (Frankfurt am Maim, DE) |-| Assignee: Sanofi-Aventis Deutschland GmbH (DE) |-| The invention relates to a dual-chamber carpule comprising a cylinder (1) comprising a bypass (3), a central plug (6) and an end plug (10), and an attachment; the invention further relates to a method for producing and filling said dual-chamber carpule. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 The superadditivity of fragment linking on affinities was quantified by systematic deconstruction of a fXa inhibitor. In their Communication (DOI: 10.1002/anie.201107091), M. Nazaré, H. Matter, and co-workers show that by connecting two fragments with a single bond, a linker contribution of -14.0 kJ?mol(-1) results, which corresponds to an affinity improvement of about 2.5 orders of magnitude relative to the sum of fragment affinities. |-| Angew Chem Int Ed Engl. |-| Nazaré M, Matter H, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Aim:AVE8134 is a structurally novel potent PPAR? agonist. The aim of this study is to investigate the efficacy of AVE8134 on lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.Methods:A cell based PPAR Gal4 transactivation assay was constructed for testing the activities of AVE8134 at 3 different PPAR isoforms in vitro. Transgenic human Apo A1 (hApo A1) mice and insulin-resistant ZDF rats were used to evaluate the effects of AVE8134 in vivo.Results:AVE8134 was (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 GAITHERSBURG, MD-(Marketwire - January 04, 2012) - Highlighted Links http:/www.neximmune.com NexImmune, an early stage biopharmaceutical company, announced today the appointment of Kenneth Carter, PhD, as the company's President and Chief Executive Officer, and Professor Jonathan Schneck, MD, PhD, as Chairman of the company's Clinical and Scientific Advisory Board. At the same time, NexImmune announced that the company has licensed the Artificial IMmune (AIM) nanotechnology for (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8088799 |-| Title: Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor |-| Inventors: Linz; Wolfgang (Mainz, DE), Schindler; Ursula (Bad Soden, DE) |-| Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE) |-| This invention is directed to a pharmaceutical composition comprising the sodium-hydrogen exchanger (NHE) inhibitor cariporide and an angiotensin converting enzyme (ACE) inhibitor (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8088765 |-| Title: Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof |-| Inventors: De Peretti; Danielle (Paris, FR), Evanno; Yannick (Paris, FR), Machnik; David (Paris, FR), Rakotoarisoa-Rameix; Nathalie (Paris, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| Compounds of formula (I): #STR00001# wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, Het and X are as defined in the disclosure, or an acid addition salt (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8088925 |-| Title: Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors |-| Inventors: Wagner; Michael (Frankfurt am Main, DE), Urmann; Matthias (Frankfurt am Main, DE), Wehner; Volkmar (Frankfurt am Main, DE), Lorenz; Martin (Frankfurt am Main, DE), Bauer; Armin (Frankfurt am Main, DE), Nazare; Marc (Frankfurt am Main, DE), Matter; Hans (Frankfurt am Main, DE) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The present invention relates to (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8088827 |-| Title: Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |-| Inventors: Nisato; Dino (Saint Georges D'Orques, FR), Roccon; Alain (Sainte-Croix-de-Quintillargues, FR), Cosnier-Pucheu; Sylvie (Villeneuve-les-Maguelone, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The present invention relates to the use of irbesartan for the preparation of medicinal products that are useful for preventing or (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus, Sanofi-Aventis) with the expectation of retaining native human insulin's superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 The antibiotic telithromycin (Ketek, Sanofi-aventis) had two of three treatment indications withdrawn after postmarketing reports of serious and fatal adverse events. The rationale for the withdrawal of specific indications (acute bacterial sinusitis and acute exacerbations of chronic bronchitis), while permitting the drug to remain available for the treatment of community-acquired pneumonia, focused on the lack of demonstrated efficacy from clinical trials that included an active control to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Objective: To compare the persistence (treatment duration) of basal insulin supported oral therapy (BOT) using insulin glargine (GLA) or NPH insulin (NPH) in Type-2 diabetic patients. Methods: This retrospective cohort study reports results from an analysis of claims data from prescriptions for ambulatory patients within the German Statutory Health Insurance scheme. The study is based on claims data from more than 80% of German community pharmacies. Treatment duration until switching to a (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8084198 |-| Title: Use of a GIP promoter polymorphism |-| Inventors: Kozian; Detlef (Frankfurt am Main, DE), Herrmann; Matthias (Frankfurt am Main, DE), Siegler; Karl-Ernst (Ludwigshafen, DE), Deleuze; Jean-Francois (Paris, FR), Ricard; Sylvain (Paris, FR), Mace; Sandrine (Paris, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The use of the single nucleotide polymorphism (SNP) at position -(97) of the GIP gene for the identification of a cardiovascular disease or of an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 More than just the sum of its parts: The superadditivity effect of fragment linking on ?G was quantified by deconstructing two fXa inhibitors with congeneric fragments, but different linkers. By connecting both fragments with a single bond, a high linker contribution ?G(link) of -14.0 kJ?mol(-1) results, which corresponds to an improvement in affinity by around 2.5 orders of magnitude relative to the sum of fragment ?G values. |-| Angew Chem Int Ed Engl. |-| Nazaré M, Matter H, Will (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 JERUSALEM-(BUSINESS WIRE)- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) announced today that Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and will join the company in March 2012. Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis. After six intensive years, Dr. Gerard van Odijk, Teva Europe s current President and CEO has decided to step down. In the next few (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8080547 |-| Title: Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof |-| Inventors: Even; Luc (Paris, FR), Hoornaert; Christian (Paris, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The invention relates to the triazolopyridine carboxamide derivative and trizolopyrimidine carboxamide derivative of general Formula (I): #STR00001# Wherein X, R.sub.1 and R.sub.2 are as defined herein. (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8080569 |-| Title: Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |-| Inventors: Zoller; Gerhard (Schoneck, DE), Strobel; Hartmut (Frankfurt am Main, DE), Will; David William (Frankfurt am Main, DE), Wohlfart; Paulus (Frankfurt am Main, DE) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The present invention relates to derivatives of imidazo[2,1-b]thiazoles of formula I, #STR00001# in which R, R1 to R3 and n have the meanings indicated in the claims, which (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Celivarone in Atrial Fibrillation/Atrial Flutter.?Introduction:?Celivarone, a new noniodinated benzofuran derivative pharmacologically related to dronedarone and amiodarone, has been shown to have antiarrhythmic properties at a molecular level. The purpose of the 2 trials presented here (MAIA and CORYFEE) was to assess celivarone efficacy in the maintenance of sinus rhythm postcardioversion and for the conversion of atrial fibrillation (AF)/atrial flutter (AFL). Methods and Results:?In (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 Sodium-activated (KNa) channels have been suggested to set the resting potential, modulate slow after-hyper polarizations, and control bursting behaviour or spike frequency adaptation (Bhattacharjee and Kaczmarek, 2005). One of the genes that encodes KNa channels is called Slack (Kcnt1, Slo2.2). Recent studies have found that Slack channels are highly expressed in nociceptive dorsal root ganglionic (DRG) neurons and were shown to modulate their firing frequency (Nuwer, et al., 2010). (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 New York, NY; Danvers, MA December 15, 2011 HCPro, the leading provider of integrated information, education, training, and consulting for the US healthcare regulatory and compliance markets, has purchased Luxid, the award-winning Semantic Content Enrichment software solution from TEMIS. HCPro will use the TEMIS software solution to speed the development of its new database and compliance products thanks to automated knowledge extraction from content. With Luxid, HCPro will also strengthen the (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8076324 |-| Title: Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them |-| Inventors: Bohme; Thomas (Nauheim, DE), Gerlach; Uwe (Hattersheim, DE), Gretzke; Dirk (Frankfurt, DE), Kleemann; Heinz-Werner (Bischofsheim, DE), Pfeiffer-Marek; Stefania (Frankfurt, DE), Vollert; Henning (Bad Segeberg, DE), Altenburger; Jean-Michel (Saint Remy les Chevreuse, FR), Mallart; Sergio (Orsay, FR) |-| Assignee: (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8076336 |-| Title: Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments |-| Inventors: Heinelt; Uwe (Frankfurt am Main, DE), Wehner; Volkmar (Frankfurt am Main, DE), Herrmann; Matthias (Frankfurt am Main, DE), Schoenafinger; Karl (Alzenau, DE), Steinhagen; Henning (Sulzbach, DE), Scheiper; Bodo (Frankfurt am Main, DE) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The invention relates to novel compounds of formula I #STR00001# where R1, R2, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8076340 |-| Title: Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |-| Inventors: Galli; Frederic (Vaucresson, FR), Leclerc; Odile (Massy, FR), Lochead; Alistair (Charenton le Pont, FR), Vache; Julien (Paris, FR) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The invention relates to compounds having general formula (I), wherein R is as defined herein. #STR00001# The invention also relates to acid addition (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=7 Top 10: 2011 in Review Here it is, our fourth annual Top 10 Year in Review-a wholly subjective look at the 10 stories or trends that shaped the year in biotech. Drum roll, please. #10 Bad PR. FDA has made an effort to get unapproved drugs off the market by offering incentives to the companies that choose to jump through the proper hoops and get formal approvals. That's just what K-V Pharmaceuticals did for hydroxyprogesterone caproate, a drug used to prevent preterm labor. And it duly hiked (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=7 ScienceDaily (Dec. 7, 2011) Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin. See Also: Health & Medicine Stem Cells Sickle Cell Anemia Genes Gene Therapy Lymphoma Leukemia Reference Sickle-cell disease Embryonic stem cell Leukemia Haemophilia The technique uses cells from a patient's skin to generate induced (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial flutter, as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination and the Centre for Health Economics, both at the University of York, were (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8071601 |-| Title: Aminoquinoline derivatives and their use as adenosine A3 ligands |-| Inventors: Aranyi; Peter (Budapest, HU), Batori; Sandor (Budapest, HU), Timari; Geza (Vecses, HU), Boer; Kinga (Pomaz, HU), Kapui; Zoltan (Budapest, HU), Mikus; Endre (Budapest, HU), Urban-Szabo; Katalin (Budapest, HU), Gerber; Katalin (Budapest, HU), Vargane Szeredi; Judit (Budapest, HU), Finet; Michel (Budapest, HU) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The present invention (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=7 United States Patent: 8071297 |-| Title: Method for the diagnosis and treatment of cardiovascular diseases |-| Inventors: Kozian; Detlef (Frankfurt am Main, DE), Herrmann; Matthias (Frankfurt am Main, DE), Leeuw; Thomas (Frankfurt am Main, DE), Renner; Wilfried (Graz, AT), Maerz; Winfried (Offenbach, DE) |-| Assignee: Sanofi-Aventis (Paris, FR) |-| The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 In the 1990s, drug companies focused their resources on chemistry-based proprietary blockbuster compounds (small molecules) for chronic diseases that could bring in several billion dollars in a short period of time. Since then, the focus has turned to biologics (proteins/high MW molecules) such as anticancer agents, antibodies, and so on. Vaccines, in contrast, are a rather slow-growing market, administered only a few times per patient, low priced, and often undifferentiated. Due to the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=7 BACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. METHODS: In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic pulmonary embolism (…)